KR100669174B1 - 유기화합물 함유 조성물 - Google Patents

유기화합물 함유 조성물 Download PDF

Info

Publication number
KR100669174B1
KR100669174B1 KR1020007008399A KR20007008399A KR100669174B1 KR 100669174 B1 KR100669174 B1 KR 100669174B1 KR 1020007008399 A KR1020007008399 A KR 1020007008399A KR 20007008399 A KR20007008399 A KR 20007008399A KR 100669174 B1 KR100669174 B1 KR 100669174B1
Authority
KR
South Korea
Prior art keywords
epothilone
water
polyethylene glycol
epothilones
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020007008399A
Other languages
English (en)
Korean (ko)
Other versions
KR20010040534A (ko
Inventor
반후게베스트피터
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100669174(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9802451.6A external-priority patent/GB9802451D0/en
Priority claimed from GBGB9813646.8A external-priority patent/GB9813646D0/en
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20010040534A publication Critical patent/KR20010040534A/ko
Application granted granted Critical
Publication of KR100669174B1 publication Critical patent/KR100669174B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020007008399A 1998-02-05 1999-02-03 유기화합물 함유 조성물 Expired - Fee Related KR100669174B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9802451.6 1998-02-05
GBGB9802451.6A GB9802451D0 (en) 1998-02-05 1998-02-05 Organic compounds
GB9813646.8 1998-06-24
GBGB9813646.8A GB9813646D0 (en) 1998-06-24 1998-06-24 Organic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020057022710A Division KR20060002022A (ko) 1998-02-05 1999-02-03 유기화합물 함유 조성물

Publications (2)

Publication Number Publication Date
KR20010040534A KR20010040534A (ko) 2001-05-15
KR100669174B1 true KR100669174B1 (ko) 2007-01-17

Family

ID=26313062

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020057022710A Ceased KR20060002022A (ko) 1998-02-05 1999-02-03 유기화합물 함유 조성물
KR1020007008399A Expired - Fee Related KR100669174B1 (ko) 1998-02-05 1999-02-03 유기화합물 함유 조성물
KR1020087003239A Ceased KR20080016756A (ko) 1998-02-05 1999-02-03 유기화합물 함유 조성물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020057022710A Ceased KR20060002022A (ko) 1998-02-05 1999-02-03 유기화합물 함유 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020087003239A Ceased KR20080016756A (ko) 1998-02-05 1999-02-03 유기화합물 함유 조성물

Country Status (36)

Country Link
US (5) US20030203876A1 (enExample)
EP (1) EP1052974B1 (enExample)
JP (2) JP4644364B2 (enExample)
KR (3) KR20060002022A (enExample)
CN (2) CN100396276C (enExample)
AR (1) AR017979A1 (enExample)
AT (1) ATE431733T1 (enExample)
AU (1) AU753519B2 (enExample)
BE (1) BE1012140A3 (enExample)
BR (1) BR9907647B1 (enExample)
CA (1) CA2320182C (enExample)
CL (1) CL2003002786A1 (enExample)
CO (1) CO4920246A1 (enExample)
CY (1) CY1109311T1 (enExample)
CZ (1) CZ303168B6 (enExample)
DE (1) DE69940904D1 (enExample)
DK (1) DK1052974T3 (enExample)
ES (1) ES2324378T3 (enExample)
FR (1) FR2774909B1 (enExample)
HU (1) HUP0101564A3 (enExample)
ID (1) ID26549A (enExample)
IL (2) IL137550A0 (enExample)
IT (1) IT1313549B1 (enExample)
MX (1) MXPA00007681A (enExample)
MY (1) MY125921A (enExample)
NO (2) NO329376B1 (enExample)
NZ (1) NZ506389A (enExample)
PE (1) PE20000272A1 (enExample)
PL (1) PL201329B1 (enExample)
PT (1) PT1052974E (enExample)
RU (1) RU2214246C2 (enExample)
SI (1) SI1052974T1 (enExample)
SK (2) SK287775B6 (enExample)
TR (1) TR200002299T2 (enExample)
TW (1) TW457095B (enExample)
WO (1) WO1999039694A2 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
EP1440973A3 (de) 1995-11-17 2004-10-20 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilonderivate, Herstellung und Mittel
PL193229B1 (pl) 1996-11-18 2007-01-31 F Biotechnologische Forschung Epotylon C, epotylon D, epotylon E i epotylon F, sposób biotransformacji epotylonu A, sposób biotransformacji epotylonu B oraz środek leczniczy
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
GB9802451D0 (en) * 1998-02-05 1998-04-01 Ciba Geigy Ag Organic compounds
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
EP1135470A2 (en) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
EE05301B1 (et) 2001-01-25 2010-06-15 Bristol-Myers Squibb Company Meetod epotilooni analooge sisaldavate ravimvormide valmistamiseks ning nende kasutamine ravimi valmistamiseks
RU2003126171A (ru) 2001-01-25 2005-02-27 Бристол-Маерс Сквибб Компани (Us) Парентеральный состав, содержащий аналоги эпотилона
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
IL156578A0 (en) * 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for pharmaceutical use and pharmaceutical preparations including an epothilone analog
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EP1368030A1 (en) 2001-02-20 2003-12-10 Bristol-Myers Squibb Company Epothilone derivatives for the treatment of refractory tumors
EE200300396A (et) 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaatide kasutamine refraktaarsete kasvajate raviks
WO2002072085A1 (en) 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
DE60229922D1 (de) * 2001-03-19 2009-01-02 Novartis Ag Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend
WO2002098868A1 (en) 2001-06-01 2002-12-12 Bristol-Myers Squibb Company Epothilone derivatives
AU2008203233B2 (en) * 2001-07-19 2010-04-29 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
NZ533940A (en) 2002-01-14 2007-06-29 Novartis Ag Combinations comprising epothilones and anti-metabolites
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
BR0311714A (pt) * 2002-06-10 2005-03-01 Novartis Ag Combinações que compreendem epotilonas e seus usos farmacêuticos
AU2003243561A1 (en) 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
WO2004018478A2 (en) 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
RS20050235A (sr) 2002-09-23 2007-06-04 Bristol Myers Squibb Company, Postupci za pripremanje,izolaciju i prečišćavanje epotilona b i kristalne strukture epotilona b dobijene primenom x-zraka
JP2006504743A (ja) 2002-10-09 2006-02-09 コーザン バイオサイエンシス インコーポレイテッド 治療製剤
DE60310975T2 (de) * 2002-10-15 2007-07-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Verwendung von epothilone zur behandlung hyperparathyreoidismus
KR100996996B1 (ko) 2002-11-07 2010-11-25 코산 바이오사이언시즈, 인코포레이티드 트랜스-9,10-디히드로에포틸론 ｃ 및 ｄ, 그것의 유사체 및 그것의 제조 방법
BRPI0415428A (pt) * 2003-10-09 2006-12-05 Kosan Biosciences Inc formulações terapêuticas
EP1670487A4 (en) * 2003-10-09 2008-05-21 Kosan Biosciences Inc THERAPEUTIC FORMULATIONS
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
WO2005073223A1 (ja) * 2004-01-29 2005-08-11 Eisai R & D Management Co., Ltd. マクロライド系化合物の安定化方法
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
CN100409846C (zh) * 2005-11-22 2008-08-13 菏泽睿鹰制药集团有限公司 一种埃坡霉素b脂质体制剂及应用
WO2008019820A2 (en) 2006-08-16 2008-02-21 Novartis Ag Crystal form of epothilone b and use in pharmaceutical compositions
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
CN101642453B (zh) * 2009-09-15 2011-03-16 湖南迪诺制药有限公司 一种含有埃坡霉素b的药物制剂
GB201505347D0 (en) * 2015-03-27 2015-05-13 Salupont Consulting Ltd Sterilisation of s-nitrosothiols
MX2020007270A (es) * 2017-09-27 2020-08-17 Novartis Ag Formulacion parenteral que comprende siponimod.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025929A1 (en) * 1996-12-13 1998-06-18 Novartis Ag Epothilone analogs

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
IL27947A (en) * 1967-05-09 1972-07-26 Weitzman J Method for the production of thermoplastic resin particles and of mixtures of such particles with additives
JPS56115855A (en) * 1980-02-19 1981-09-11 Toyota Motor Corp Method and apparatus for controlling ignition timing of engine
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
US5216011A (en) * 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
DE4138042C2 (de) * 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
JPH0753396A (ja) * 1993-08-19 1995-02-28 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物，その製造法および用途
CA2092271C (en) * 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
HUT73844A (en) * 1994-11-11 1996-09-30 Chinoin Gyogyszer Es Vegyeszet New taxol complexes and pharmaceutical compositions containing them
JP3934705B2 (ja) * 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
EP1440973A3 (de) * 1995-11-17 2004-10-20 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilonderivate, Herstellung und Mittel
CZ297979B6 (cs) * 1996-03-12 2007-05-16 Pg-Txl Company, L. P. Kompozice obsahující protinádorové lécivo konjugované s ve vode rozpustným polymerem, její pouzití pro výrobu léciva a implantovatelná lékarská pomucka
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
EP0977563B1 (en) * 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025929A1 (en) * 1996-12-13 1998-06-18 Novartis Ag Epothilone analogs

Also Published As

Publication number Publication date
PL201329B1 (pl) 2009-03-31
CL2003002786A1 (es) 2005-02-04
EP1052974A2 (en) 2000-11-22
PT1052974E (pt) 2009-08-07
WO1999039694A3 (en) 1999-09-23
NO329376B1 (no) 2010-10-04
CZ303168B6 (cs) 2012-05-09
SK287487B6 (sk) 2010-11-08
DE69940904D1 (de) 2009-07-02
ID26549A (id) 2001-01-18
BR9907647A (pt) 2000-11-14
SK287775B6 (sk) 2011-09-05
US20080221065A1 (en) 2008-09-11
ITMI990208A1 (it) 2000-08-04
JP2002502810A (ja) 2002-01-29
NO20003930L (no) 2000-10-04
MY125921A (en) 2006-08-30
CA2320182C (en) 2008-11-25
CN100396276C (zh) 2008-06-25
US20060127423A1 (en) 2006-06-15
CN1623543A (zh) 2005-06-08
EP1052974B1 (en) 2009-05-20
NZ506389A (en) 2003-07-25
AU753519B2 (en) 2002-10-17
US20030203876A1 (en) 2003-10-30
KR20010040534A (ko) 2001-05-15
WO1999039694A2 (en) 1999-08-12
BE1012140A3 (fr) 2000-05-02
ES2324378T3 (es) 2009-08-05
FR2774909B1 (fr) 2000-07-28
PE20000272A1 (es) 2000-04-17
AR017979A1 (es) 2001-10-24
HUP0101564A2 (hu) 2001-11-28
AU2722699A (en) 1999-08-23
IL137550A (en) 2010-06-30
TR200002299T2 (tr) 2000-11-21
CN1292683A (zh) 2001-04-25
RU2214246C2 (ru) 2003-10-20
KR20080016756A (ko) 2008-02-21
KR20060002022A (ko) 2006-01-06
PL342629A1 (en) 2001-06-18
CY1109311T1 (el) 2014-07-02
JP4644364B2 (ja) 2011-03-02
HK1033809A1 (en) 2001-09-28
TW457095B (en) 2001-10-01
FR2774909A1 (fr) 1999-08-20
MXPA00007681A (es) 2003-07-14
SI1052974T1 (sl) 2009-10-31
HUP0101564A3 (en) 2002-06-28
NO20003930D0 (no) 2000-08-03
US20070060627A1 (en) 2007-03-15
IT1313549B1 (it) 2002-09-09
NO20100302L (no) 2000-10-04
IL137550A0 (en) 2001-07-24
US20110124691A1 (en) 2011-05-26
CO4920246A1 (es) 2000-05-29
ATE431733T1 (de) 2009-06-15
CZ20002834A3 (cs) 2000-11-15
JP2010090147A (ja) 2010-04-22
BR9907647B1 (pt) 2014-04-01
CA2320182A1 (en) 1999-08-12
DK1052974T3 (da) 2009-08-10
SK11702000A3 (sk) 2001-01-18

Similar Documents

Publication Publication Date Title
KR100669174B1 (ko) 유기화합물 함유 조성물
US6683100B2 (en) Organic compounds
CN111465389B (zh) 多西他赛共缀物的药物组合物及制备方法
RU2268045C2 (ru) Лиофилизированная композиция
EP1800664B1 (en) Pharmaceutical formulations for parenteral administration comprising epothilone
KR20090106666A (ko) 유기화합물 함유 조성물
HK1105808B (en) Pharmaceutical formulations for parenteral administration comprising epothilone
HK1105808A1 (en) Pharmaceutical formulations for parenteral administration comprising epothilone
HK1033809B (en) Pharmaceutical formulation containing epothilone
HK40033919A (en) Pharmaceutical composition of docetaxel conjugate and preparation method
HK40033919B (en) Pharmaceutical composition of docetaxel conjugate and preparation method

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20121226

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20131220

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20150110

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20150110

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000